Updates

They Said It!: Lawmakers And FDA Nominee Highlight Greater Competition As Critical To Lowering Prescription Drug Prices

Mar 12, 2025

U.S. Senate Confirmation Hearing Called Attention to Big Pharma’s Egregious Read More

ICYMI: CSRxP SURVEY FINDS AMERICAN VOTERS OVERWHELMINGLY HOLD BIG PHARMA RESPONSIBLE FOR HIGH DRUG PRICES

Mar 6, 2025

Across Political Spectrum, Fabrizio Ward Finds Voters Identify Pharmaceutical Read More

CSRXP: FABRIZIO WARD SURVEY FINDS AMERICAN VOTERS OVERWHELMING HOLD BIG PHARMA COMPANIES RESPONSIBLE FOR HIGH DRUG PRICES

Feb 28, 2025

Voters Across the Political Spectrum Identify Pharmaceutical Company Profits Read More

SECOND OPINION: PhRMA REDUXES SAME DEBUNKED ARGUMENTS ON INNOVATION

Feb 26, 2025

Big Pharma’s Innovation Rhetoric Designed to Keep Drug Prices High Rather Read More

THEY SAID IT! PRESIDENT TRUMP CALLS OUT BIG PHARMA’S EGREGIOUS PRICING FOR DIABETES AND WEIGHT LOSS DRUGS IN U.S. MARKET

Feb 19, 2025

Brand Name Manufacturers’ Prices for Blockbuster GLP-1 Medications Are Read More

CSRXP STATEMENT ON CONFIRMATION OF RFK JR AS SECRETARY OF U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES

Feb 13, 2025

Campaign Looks Forward to Working with Kennedy and the Administration to Lower Read More

BIG PHARMA EARNINGS WATCH: GILEAD

Feb 13, 2025

Brand Name Drug Company Known for Egregious Product-Hopping Strategy Beats Read More

BIG PHARMA EARNINGS WATCH: ASTRAZENECA, BRISTOL MYERS SQUIBB AND ELI LILLY

Feb 12, 2025

Eli Lilly Signals Plan to Maintain Unsustainably High Prices on Blockbuster Read More

BIG PHARMA EARNINGS WATCH: MERCK AND PFIZER

Feb 7, 2025

Pharmaceutical Giants Continue to Outperform Wall Street Projections While Read More

BIG PHARMA EARNINGS WATCH: AMGEN, GSK AND NOVO NORDISK

Feb 7, 2025

Major Pharmaceutical Companies Continue Growing Revenues While Sticking With Read More

BIG PHARMA EARNINGS WATCH: ABBVIE, NOVARTIS AND ROCHE

Feb 6, 2025

Big Pharma Giants Report Higher-Than-Expected Q4 Earnings Amid Continued Price Read More

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Jan 30, 2025

Johnson & Johnson Beats Wall Street Analysts’ Expectations Fueled by Read More